Table 1.
Clinicopathologic characteristics and RB1 expression patterns across histotypes.
| HGSC | LGSC | MOC | ENOC | CCOC | Total | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| n | (%) | n | (%) | N | (%) | N | (%) | n | (%) | N | (%) | P | |
| Patients | |||||||||||||
| Number (% of total) | 5,009 | (67) | 224 | (3) | 409 | (6) | 1,033 | (14) | 761 | (10) | 7,436 | ||
| Age at diagnosis (years) | |||||||||||||
| Median | 61 | 55 | 56 | 54 | 55 | 59 | <0.0001a | ||||||
| Min–max | 21–92 | 23–88 | 23–95 | 21–91 | 27–89 | 21–95 | |||||||
| 1%–99% percentile | 37–84 | 25–87 | 24–87 | 30–84 | 33–83 | 32–84 | |||||||
| FIGO stage | |||||||||||||
| I/II | 894 | (18) | 67 | (30) | 310 | (76) | 805 | (78) | 567 | (75) | 2,643 | (36) | <0.0001b |
| III/IV | 3,841 | (77) | 137 | (61) | 57 | (14) | 147 | (14) | 168 | (22) | 4,350 | (58) | |
| Unknown | 274 | (5) | 20 | (9) | 42 | (10) | 81 | (8) | 26 | (3) | 443 | (6) | |
| Residual disease | |||||||||||||
| Absent | 1,023 | (20) | 73 | (33) | 162 | (40) | 461 | (45) | 352 | (46.3) | 2,071 | (27.9) | <0.0001b |
| Present | 1,488 | (30) | 52 | (23) | 21 | (5) | 41 | (4) | 78 | (10.2) | 1,680 | (22.6) | |
| Unknown | 2,498 | (50) | 99 | (44) | 226 | (55) | 531 | (51) | 331 | (43.5) | 3,685 | (49.6) | |
| RB1 protein | |||||||||||||
| Loss | 734 | (15) | 5 | (2) | 7 | (2) | 37 | (4) | 12 | (2) | 795 | (11) | <0.0001c |
| Retained | 3,748 | (75) | 176 | (79) | 319 | (78) | 871 | (84) | 655 | (86) | 5,769 | (78) | |
| Subclonal loss | 58 | (1) | 0 | (0) | 0 | (0) | 7 | (1) | 1 | (0) | 66 | (1) | |
| Cytoplasmic | 13 | (0) | 0 | (0) | 1 | (0) | 1 | (0) | 2 | (0) | 17 | (0) | |
| Uninterpretable | 456 | (9) | 43 | (19) | 82 | (20) | 117 | (11) | 91 | (12) | 789 | (11) | |
Abbreviations: CCOC, clear cell ovarian cancer; LGSC, low-grade serous carcinoma; MOC, mucinous ovarian cancer.
a
Kruskal–Wallis test P values are reported, excluding cases with “unknown” information.
b
χ 2 test P values are reported, excluding cases with “unknown” information.
c
χ 2 test excluding cases with subclonal loss and cytoplasmic or uninterpretable RB1 protein expression.